Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • test

      document.getElementById(“video”).style.height=document.getElementById(“video”).scr

    2025.06.06
  • At ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.

    ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.

    2025.06.04
  • Prof. Olaf Penack: Standardized GVHD Management in Europe and Future Strategies | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy

    Editor’s Note: The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of…

    2025.06.04
  • Prof. Anna Sureda, President of EBMT, on China-Europe Collaboration and the Future of Cellular Therapy | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy

    Editor’s Note:The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of the…

    2025.06.04
  • Professor Shun Lu: High Efficacy and Low Toxicity—SHR-A1811 Opens a New Era of ADC Therapy for HER2-Mutant NSCLC

    At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), the China-developed HER2-directed  antibody-drug conjugate (ADC) Trastuzumab rezetecan(SHR-A1811) made a striking appearance with new data from the HORIZON-Lung study: an objective response rate (ORR) of 74.5%, a median progression-free survival (PFS) of 11.5 months, and an interstitial lung disease (ILD) incidence of…

    2025.05.28
  • An international event focusing on cellular therapy for blood diseases is approaching! From August 17 to September 1, 2025, in Tuanbo Campus, Tianjin, China

    An international event focusing on cellular therapy for blood diseases is approaching! From August 17 to September 1, 2025, in Tuanbo Campus, Tianjin, China, the International Workshop on Cell Therapy of Blood Diseases hosted by the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science (IHCAMS) and supported by the Ministry of…

    2025.05.27
  • 50 Years of Hematopoietic Stem Cell Transplantation: Xiaojun Huang on China’s Transformative Journey

    Tracing the Origins Breaking Through Barriers: Milestones in Global Transplantation Technology In 1939, the first bone marrow transplant in human history was performed on a patient suffering from aplastic anemia…

    2025.05.21
  • Advancing AML Treatment in Asia: Insights from Professor Jianxiang Wang

    We are thrilled to share an exclusive presentation by Professor Jianxiang Wang from the Institute of Hematology, Chinese Academy of Medical Sciences. In this engaging session, Professor Wang delves into the groundbreaking findings of the Phase 3 Commodore study, recently published in Leukemia. This study provides critical new evidence on the efficacy of gilteritinib, a…

    2025.05.19
«previous next»
Recent Posts
  • The 14th Lu Daopei Hematology Forum丨Professor Huili Zhu: Evidence-Based Updates and Precision Prevention and Control — A Clinical Interpretation of the 7th Edition of the Guidelines for Invasive Fungal Disease in Hematologic Disorders
  • The 14th Lu Daopei Hematology Forum | Professor Hui Wang: Building the Foundation with Precision Diagnosis, Advancing with Intelligent Empowerment—The Clinical Value and Future Directions of Hematologic Laboratory Testing
  • The 14th Lu Daopei Hematology Forum | Peihua Lu: Fourteen Years of Staying True to the Mission and Embarking on a New Journey—The Value and Future of an Academic Platform for Hematology
  • The 14th Lu Daopei Hematology Forum | Dongchu Wang: Unlocking the Predictive Value of Cytokines and Optimizing the Entire Treatment Pathway—Research and Prospects of CD7 CAR-T as a Bridge to Transplantation
  • The 14th Lu Daopei Hematology Forum | Dr. Shu Yan: Stratified Prevention and Control, Comprehensive Management—Strategies for the Diagnosis and Treatment of Invasive Fungal Disease After Hematopoietic Stem Cell Transplantation
Recent Comments
    Archives
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top